Skip to Main Content

Try STAT+ TODAY

neurology

Most Read

First Opinion Podcast Patrick Skerrett

Listen: A doctor with ALS laments the slow pace for drug approval

Health Tech Casey Ross

In early research, an AI model detects signs of Parkinson’s using breathing patterns

Health Megan Molteni

Zapping the brain with electricity shown to boost older people’s short- and long-term memory

Health Tech Mario Aguilar

Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

In the Lab Elizabeth Cooney

New study revives a Mozart sonata as a potential epilepsy therapy

Health Mario Aguilar

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

Health Elizabeth Cooney

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

All Coverage

Biotech Allison DeAngelis

Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down

Exclusive Mario Aguilar

Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help

advertisement

Health Andrew Joseph

An Alzheimer’s therapy scores winning results, but what could it mean for patients?

Health Jonathan Wosen

Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain

Biotech Jason Mast

How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

Health Akila Muthukumar

New research finds blood tests can predict severe outcomes of brain injury

Biotech Adam Feuerstein

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

Biotech Adam Feuerstein

FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment

Biotech Ryan Cross — The Boston Globe

Can Biogen’s backup plan for Alzheimer’s succeed?

Health Tech Mario Aguilar

Startup gets green light to use Apple Watch to track Parkinson’s symptoms

First Opinion Cecille Joan Avila

The often-overlooked connection between traumatic brain injury and domestic violence

In the Lab Jonathan Wosen

The brain ‘learns’ to have seizures more efficiently and frequently over time, mouse study shows

First Opinion Bernard Zipprich

Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?

The Pharmalot View Ed Silverman

‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

Health Tech Katie Palmer

With pharma still struggling in Alzheimer’s, health tech companies want a swing

In the Lab Meghana Keshavan

With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption

Politics Nicholas Florko

An ALS therapy sets up a crucial test of the FDA’s independence

Video Chat Gideon Gil

Virtual Event – ‘Augmented’: The future of brain-controlled prosthetic limbs

In the Lab Jonathan Wosen

Scientists take key step toward unraveling the genetic roots of ALS in a pair of studies

Health Elizabeth Cooney

In ‘chemo brain,’ researchers see clues to unravel long Covid’s brain fog

In the Lab Megan Molteni

Strong new evidence suggests a virus triggers multiple sclerosis

Special Report Isabella Cueto

Jolting the brain’s circuits with electricity is moving from radical to almost mainstream therapy. Some crucial hurdles remain

Pharmalot Ed Silverman

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs

Biotech Maaisha Osman

4 epilepsy-focused biotech companies to watch

Exclusive Kate Sheridan

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s